hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 21:58:17 - browse：9384

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout Newsletter: Biotech news, including Moderna's Covid vaccine

leisure time

WSS

6 solutions to address cancer drug shortages and others

What to expect at HLTH 2023, the health care industry conference

FDA authorizes Novavax’s updated Covid

A virus, fished out of a lake, may have saved a man’s life

Colorectal cancer study finds potential in overlooked immune cell

FDA panel signals lack of confidence in Amgen cancer drug data

knowledge

hotspot

focus

Sports medicine is finally prioritizing gender equality

AI can decode, harness the power of the humane immune system

How to save PrEP access — and even expand it

The stability of $0 premiums in Medicare Advantage

In age of alternative facts, a scholarly course on calling out crap

Why Charlie Gard's case is so disturbing to Americans

Moonlake's readout produced a cash windfall. Risks remain

Bristol 'take

United colonoscopy coverage change 'may cost lives,' doctors say

IVG is promising — but it won’t replace IVF quite yet

knowledge

FDA panel signals lack of confidence in Amgen cancer drug data

Chemotherapy drug shortage eases slightly but still widespread

Why Charlie Gard's case is so disturbing to Americans

Stroke deaths set to near 10 million globally by 2050

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

VC firm General Catalyst wants to buy a health system

explore

hotspot

leisure time

knowledge